During an in-competition routine urine test, Oleksiejczuk tested positive for Clomifene, also known as Clomiphene, taken on December 30th, 2017, heading into UFC 219. Since the test results have shown positive feed back, Michal’s win over Khalil Rountree Jr. has been overturned, and is now a no content.
Oleksiejczuk’s suspension would have began the date the test was found positive, Dec. 30th, 2017, and will be eligible for re-licensing on Dec. 30th, 2018.
For those unaware, what exactly is Clomifene (Clomiphene)?
“Clomiphene is a selective estrogen receptor modulator (SERM) commonly used in female fertility brand name prescription medications, such as Clomid. In women, clomiphene acts on the pituitary gland to stimulate the release of specific hormones responsible for ovulation. In men, clomiphene can alter testosterone levels by interfering with the negative feedback loop of the hypothalamic–pituitary–gonadal axis. In clinical applications, clomiphene is used as an FDA-approved fertility treatment, and Clomid is indicated by the FDA “for the treatment of ovulatory dysfunction in women desiring pregnancy.” It may be used by women trying to become pregnant if they have medical conditions like polycystic ovary syndrome (PCOS), which prevents ovulation from happening naturally. In contrast, clomiphene is not FDA-approved for use by men for any condition. On the most recent Clomid product insert, the FDA states that are “no adequate or well-controlled studies that demonstrate the effectiveness of Clomid in the treatment of male infertility.” However, it may be prescribed off-label, meaning that a doctor may prescribe a medication for a use that is not indicated on the FDA’s approved packaging insert or label. Once the FDA approves a drug, healthcare providers can typically prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient.” – USADA.org
Here’s a basic visual breakdown of how Clomiphene works: